BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 33721619)

  • 1. A modified protein marker panel to identify four consensus molecular subtypes in colorectal cancer using immunohistochemistry.
    Li X; Larsson P; Ljuslinder I; Ling A; Löfgren-Burström A; Zingmark C; Edin S; Palmqvist R
    Pathol Res Pract; 2021 Apr; 220():153379. PubMed ID: 33721619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classification of Colorectal Cancer in Molecular Subtypes by Immunohistochemistry.
    Ten Hoorn S; Trinh A; de Jong J; Koens L; Vermeulen L
    Methods Mol Biol; 2018; 1765():179-191. PubMed ID: 29589308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple classifiers for molecular subtypes of colorectal cancer.
    Kim WG; Kim JY; Park DY
    Arab J Gastroenterol; 2017 Dec; 18(4):191-200. PubMed ID: 29241727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical and Robust Identification of Molecular Subtypes in Colorectal Cancer by Immunohistochemistry.
    Trinh A; Trumpi K; De Sousa E Melo F; Wang X; de Jong JH; Fessler E; Kuppen PJ; Reimers MS; Swets M; Koopman M; Nagtegaal ID; Jansen M; Hooijer GK; Offerhaus GJ; Kranenburg O; Punt CJ; Medema JP; Markowetz F; Vermeulen L
    Clin Cancer Res; 2017 Jan; 23(2):387-398. PubMed ID: 27459899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry-Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer.
    Li Y; Yao Q; Zhang L; Mo S; Cai S; Huang D; Peng J
    Oncologist; 2020 Dec; 25(12):e1968-e1979. PubMed ID: 32926498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus molecular subtype classification of colorectal adenomas.
    Komor MA; Bosch LJ; Bounova G; Bolijn AS; Delis-van Diemen PM; Rausch C; Hoogstrate Y; Stubbs AP; de Jong M; Jenster G; van Grieken NC; Carvalho B; Wessels LF; Jimenez CR; Fijneman RJ; Meijer GA;
    J Pathol; 2018 Nov; 246(3):266-276. PubMed ID: 29968252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2.
    Chang K; Willis JA; Reumers J; Taggart MW; San Lucas FA; Thirumurthi S; Kanth P; Delker DA; Hagedorn CH; Lynch PM; Ellis LM; Hawk ET; Scheet PA; Kopetz S; Arts J; Guinney J; Dienstmann R; Vilar E
    Ann Oncol; 2018 Oct; 29(10):2061-2067. PubMed ID: 30412224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
    Mooi JK; Wirapati P; Asher R; Lee CK; Savas P; Price TJ; Townsend A; Hardingham J; Buchanan D; Williams D; Tejpar S; Mariadason JM; Tebbutt NC
    Ann Oncol; 2018 Nov; 29(11):2240-2246. PubMed ID: 30247524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
    Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
    PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A consensus molecular subtypes classification strategy for clinical colorectal cancer tissues.
    de Back TR; Wu T; Schafrat PJ; Ten Hoorn S; Tan M; He L; van Hooff SR; Koster J; Nijman LE; Vink GR; Beumer IJ; Elbers CC; Lenos KJ; Sommeijer DW; Wang X; Vermeulen L
    Life Sci Alliance; 2024 Aug; 7(8):. PubMed ID: 38782602
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Consensus Molecular Subtypes and Molecular Markers With Clinical Outcomes in Patients With Metastatic Colorectal Cancer: Biomarker Analyses From LUME-Colon 1.
    Lenz HJ; Argiles G; Yoshino T; Tejpar S; Ciardiello F; Braunger J; Salnikov AV; Gabrielyan O; Schmid R; Höfler J; Kitzing T; Van Cutsem E
    Clin Colorectal Cancer; 2021 Mar; 20(1):84-95.e8. PubMed ID: 33041226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A panel of DNA methylation markers for the classification of consensus molecular subtypes 2 and 3 in patients with colorectal cancer.
    van den Berg I; Smid M; Coebergh van den Braak RRJ; van de Wiel MA; van Deurzen CHM; de Weerd V; Martens JWM; IJzermans JNM; Wilting SM
    Mol Oncol; 2021 Dec; 15(12):3348-3362. PubMed ID: 34510716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenotypic subtypes predict outcomes in colorectal cancer.
    Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
    Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.
    Smeby J; Sveen A; Merok MA; Danielsen SA; Eilertsen IA; Guren MG; Dienstmann R; Nesbakken A; Lothe RA
    Ann Oncol; 2018 May; 29(5):1227-1234. PubMed ID: 29518181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and Validation of a Gene Signature Classifier for Consensus Molecular Subtyping of Colorectal Carcinoma in a CLIA-Certified Setting.
    Morris JS; Luthra R; Liu Y; Duose DY; Lee W; Reddy NG; Windham J; Chen H; Tong Z; Zhang B; Wei W; Ganiraju M; Broom BM; Alvarez HA; Mejia A; Veeranki O; Routbort MJ; Morris VK; Overman MJ; Menter D; Katkhuda R; Wistuba II; Davis JS; Kopetz S; Maru DM
    Clin Cancer Res; 2021 Jan; 27(1):120-130. PubMed ID: 33109741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a miRNA-based classifier for detection of colorectal cancer molecular subtypes.
    Adam RS; Poel D; Ferreira Moreno L; Spronck JMA; de Back TR; Torang A; Gomez Barila PM; Ten Hoorn S; Markowetz F; Wang X; Verheul HMW; Buffart TE; Vermeulen L
    Mol Oncol; 2022 Jul; 16(14):2693-2709. PubMed ID: 35298091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RHBDD1 promotes colorectal cancer metastasis through the Wnt signaling pathway and its downstream target ZEB1.
    Zhang M; Miao F; Huang R; Liu W; Zhao Y; Jiao T; Lu Y; Wu F; Wang X; Wang H; Zhao H; Ju H; Miao S; Wang L; Song W
    J Exp Clin Cancer Res; 2018 Feb; 37(1):22. PubMed ID: 29426364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS Mutation and Consensus Molecular Subtypes 2 and 3 Are Independently Associated with Reduced Immune Infiltration and Reactivity in Colorectal Cancer.
    Lal N; White BS; Goussous G; Pickles O; Mason MJ; Beggs AD; Taniere P; Willcox BE; Guinney J; Middleton GW
    Clin Cancer Res; 2018 Jan; 24(1):224-233. PubMed ID: 29061646
    [No Abstract]   [Full Text] [Related]  

  • 19. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications.
    Soldevilla B; Carretero-Puche C; Gomez-Lopez G; Al-Shahrour F; Riesco MC; Gil-Calderon B; Alvarez-Vallina L; Espinosa-Olarte P; Gomez-Esteves G; Rubio-Cuesta B; Sarmentero J; La Salvia A; Garcia-Carbonero R
    Eur J Cancer; 2019 Dec; 123():118-129. PubMed ID: 31678770
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JARID1B promotes colorectal cancer proliferation and Wnt/β-catenin signaling via decreasing CDX2 level.
    Huang D; Xiao F; Hao H; Hua F; Luo Z; Huang Z; Li Q; Chen S; Cheng X; Zhang X; Fang W; Hu X; Liu F
    Cell Commun Signal; 2020 Oct; 18(1):169. PubMed ID: 33109187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.